WallStreetZenWallStreetZen

NASDAQ: NAUT
Nautilus Biotechnology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their NAUT stock forecasts and price targets.

Forecast return on equity

Is NAUT forecast to generate an efficient return?

Company
N/A
Industry
352.46%
Market
205.37%

Forecast return on assets

Is NAUT forecast to generate an efficient return on assets?

Company
N/A
Industry
121.28%

NAUT earnings per share forecast

What is NAUT's earnings per share in the next 2 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.62
Avg 2 year Forecast
-$0.48

NAUT revenue forecast

What is NAUT's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$1.5M
Avg 2 year Forecast
$10.7M
Avg 3 year Forecast
$29.7M

NAUT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAUT$2.03N/AN/A
SLN$5.43$55.00+912.89%Strong Buy
STTK$4.06$4.00-1.48%Buy
TARA$6.67$23.50+252.32%Strong Buy
QSI$1.21$1.50+23.97%Hold
View Top Biotech Stocks

Nautilus Biotechnology Stock Forecast FAQ

What is NAUT's earnings growth forecast for 2026-2027?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.87%.

Nautilus Biotechnology's earnings in 2026 is -$62,814,000.On average, 4 Wall Street analysts forecast NAUT's earnings for 2026 to be -$78,587,047, with the lowest NAUT earnings forecast at -$81,694,153, and the highest NAUT earnings forecast at -$74,267,412.

In 2027, NAUT is forecast to generate -$60,550,675 in earnings, with the lowest earnings forecast at -$58,176,139 and the highest earnings forecast at -$62,331,578.

If you're new to stock investing, here's how to buy Nautilus Biotechnology stock.

What is NAUT's revenue growth forecast for 2026-2028?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.

Nautilus Biotechnology's revenue in 2026 is $0.On average, 4 Wall Street analysts forecast NAUT's revenue for 2026 to be $193,246,837, with the lowest NAUT revenue forecast at $0, and the highest NAUT revenue forecast at $397,861,134. On average, 3 Wall Street analysts forecast NAUT's revenue for 2027 to be $1,352,727,857, with the lowest NAUT revenue forecast at $1,299,679,705, and the highest NAUT revenue forecast at $1,392,513,970.

In 2028, NAUT is forecast to generate $3,748,988,631 in revenue, with the lowest revenue forecast at $3,601,969,469 and the highest revenue forecast at $3,859,253,003.

What is NAUT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NAUT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 121.28%.

What is NAUT's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: NAUT) Nautilus Biotechnology's current Earnings Per Share (EPS) is -$0.50. On average, analysts forecast that NAUT's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.65, and the highest EPS forecast at -$0.59. In 2027, NAUT's EPS is forecast to hit -$0.48 (min: -$0.46, max: -$0.49).

What is NAUT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NAUT) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.